• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how we’re building a company where people come first.

    Learn about our company

    • Culture
    • Mission & Vision
    • Management Team
    • Board of Directors
    • Partnerships
    • Careers

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
      • Proprietary Manufacturing
    • Clinical Trials
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCE®
  • Responsibility

    Responsibility

    See how we’re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility Report

    Our Responsibility Report reflects the culture and purpose we live by every day. We are committed to reporting annually on our progress and commitments.

    Learn more

  • Company
    • Company
    • Culture
    • Mission & Vision
    • Management Team
      Post Type Description
    • Board of Directors
      Post Type Description
    • Partnerships
    • Careers
  • Patients
    • Patients
    • Disease Areas
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
      • Proprietary Manufacturing
    • Clinical Trials
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCE®
  • Responsibility
    • Responsibility
    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
      • Governance we uphold
      • Global Healthcare Compliance
      • Policies & Disclosures

Pipeline

We focus our research on diseases that have typically been overlooked and underserved

Whether we start from drug discovery or pick up an opportunity mid-pipeline, our team’s seamless coordination across functions and unwavering focus on transforming patients’ lives enable us to advance product candidates at any stage.

For more information on our approved product, visit our Therapies page.

Jump to:

  • Mycobacterium avium complex (MAC) Lung Disease
  • Neutrophil-Driven Inflammatory Conditions
  • Additional Rare Pulmonary Diseases
  • Genetic Diseases
  • Pre-Clinical Research

Product pipeline

Mycobacterium avium complex (MAC) Lung Disease

Preclinical Phase 1 Phase 2 Phase 3 Commercial

ARIKAYCE® (Amikacin Liposome Inhalation Suspension)*

Refractory MAC Lung Disease

Commercial

Nontuberculous mycobacterial (NTM) lung disease is a rare and serious disorder most commonly caused by a group of bacteria called Mycobacterium avium complex (MAC).1 People who have bronchiectasis, COPD, and asthma are at greater risk of getting NTM lung disease.2,3,4

Amikacin Liposome Inhalation Suspension

MAC Lung Disease

Phase 3

Nontuberculous mycobacterial (NTM) lung disease is a rare and serious disorder most commonly caused by a group of bacteria called Mycobacterium avium complex (MAC).1 People who have bronchiectasis, COPD, and asthma are at greater risk of getting NTM lung disease.2,3,4

Neutrophil-Driven Inflammatory Conditions

Preclinical Phase 1 Phase 2 Phase 3 Commercial

Brensocatib: DPP1 Inhibitor

Non-Cystic Fibrosis Bronchiectasis

Phase 3

Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic pulmonary disorder in which the bronchi become permanently dilated due to a vicious cycle of inflammation and complications from prior infections.5,6 The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations.

Brensocatib: DPP1 Inhibitor

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

Phase 2

CRS without nasal polyps is a chronic inflammatory process of the mucus membranes inside the sinuses. The most common symptoms include a decreased sense of smell and facial pain.7

Brensocatib: DPP1 Inhibitor

Hidradenitis Suppurativa (HS)

Phase 2

HS is a chronic relapsing inflammatory disorder, characterized by painful, inflamed, and swollen lesions affecting hair follicles, often in the armpits, groin, and skin folds.8

Additional Rare Pulmonary Diseases

Preclinical Phase 1 Phase 2 Phase 3 Commercial

Treprostinil Palmitil Inhalation Powder (TPIP)

Pulmonary Hypertension associated with Interstitial Lung Diseases (PH-ILD)

Phase 2

Interstitial lung diseases (ILD) comprise a large group of diseases that cause fibrosis (scarring) of the lungs. Pulmonary hypertension (high blood pressure in the lungs) is a common and important complication of several ILDs that is associated with reduced exercise capacity and poor prognosis.9,10 PH-ILD is also known as WHO Group 3 Pulmonary Hypertension.

Treprostinil Palmitil Inhalation Powder (TPIP)

Pulmonary Arterial Hypertension (PAH)

Phase 2

Pulmonary arterial hypertension (PAH) is a serious, progressive, rare disease involving narrowing and constriction of the pulmonary arteries that carry blood from the right side of the heart to the lungs.11 PAH is also known as WHO Group 1 Pulmonary Hypertension.

Genetic Diseases

Preclinical Phase 1 Phase 2 Phase 3 Commercial

INS1201: Gene Therapy

Duchenne Muscular Dystrophy (DMD)

Pre-clinical

DMD is caused by a genetic mutation that prevents the body from producing dystrophin, a protein that muscles need to work properly. Without it, muscle cells become damaged and weaken.12 DMD is the most common childhood onset form of muscular dystrophy and affects males almost exclusively.13

Pre-Clinical Research

Preclinical Phase 1 Phase 2 Phase 3 Commercial

INS1202: Gene Therapy

Amyotrophic Lateral Sclerosis (ALS)

Pre-clinical

ALS is a progressive neurological disease that affects the nerve cells in the brain and spinal cord that control voluntary muscle movement and breathing. As these nerve cells degenerate, the body’s muscles begin to weaken and waste away. Eventually, the brain loses its ability to control voluntary movements like walking, talking, chewing, and breathing. Most people with ALS die of respiratory failure within three to five years from initial symptom onset.14

INS1203: Gene Therapy

Stargardt Disease

Pre-clinical

Stargardt disease is a rare genetic eye disease caused by the buildup of fatty material on the macula, the small part of the retina needed for sharp, central vision.15 The disease leads to the loss of central vision in both eyes, typically beginning in childhood. Today, there are no treatments available for the disease, and management options focus on optimizing patients’ remaining sight.

Next-Generation DPP1 Inhibitor

Multiple indications

Pre-clinical

Other Pre-Clinical Research

Multiple indications

Pre-clinical

The safety and efficacy of investigational products and/or investigational uses of commercial products have not been approved by any health authority.

* In the U.S., as a condition of accelerated approval, Insmed is conducting an additional clinical study to support full approval. Full approval has been granted in Europe and Japan.

References

  1. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9-16.
  2. Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis.2013;17(11):e1000-e1004.
  3. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256-262.
  4. Fritscher LG, Marras TK, Bradi AC, Fritscher CC, Balter MS, Chapman KR. Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest. 2011;139(1):23-27.
  5. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013 (Weycker). https://www.ncbi.nlm.nih.gov/pubmed/28555504. Accessed December 2020.
  6. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity (Flume). https://www.ncbi.nlm.nih.gov/pubmed/30215383. Accessed December 2020.
  7. Cho SH, Kim DW, Gevaert P. Chronic Rhinosinusitis without Nasal Polyps. J Allergy Clin Immunol Pract. 2016 ; 4(4): 575–582.
  8. Phan K, Charlton O, Smith SD. Global Prevalence of Hidradenitis Suppurative and Geographical Variation—Systematic Review and Meta-Analysis. Phan et al. Biomedical Dermatology (2020) 4:2.
  9. American Lung Association. Interstitial Lung Disease. https://www.lung.org/lung-health-diseases/lung-disease-lookup/interstitial-lung-disease. Accessed January 2021.
  10. Caminati A. Pulmonary hypertension in chronic interstitial lung diseases. European Respiratory Review 2013 22: 292-301 https://err.ersjournals.com/content/22/129/292. Accessed January 2021.
  11. Pulmonary Hypertension Association. About Pulmonary Hypertension. https://phassociation.org/types-pulmonary-hypertension-groups/. Accessed January 2021.
  12. Muscular Dystrophy Association. Duchenne Muscular Dystrophy (DMD). https://www.mda.org/disease/duchenne-muscular-dystrophy. Accessed April 2023.
  13. National Institute of Child Health and Human Development. What are the types and symptoms of muscular dystrophy (MD)? https://www.nichd.nih.gov/health/topics/musculardys/conditioninfo/types. Accessed April 2023.
  14. National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS). https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als. Accessed February 2024.
  15. National Eye Institute. Stargardt Disease. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease. Accessed March 2023.

Clinical Trials

To make a real-world impact, it’s vital that we understand real-life challenges. Our clinical trials are designed in collaboration with patients to ensure their insights and needs are considered.

Learn more about our clinical trials

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy Choices

© 2025 Insmed Incorporated. All Rights Reserved.